Development of poly-ɛ-caprolactone nanoparticles for lung cancer treatment

Faisalina Ahmad Fisol, Habibah Abd. Wahab


Nanoparticles (NPs) were developed in this research using poly-ɛ-caprolactone (PCL) biodegradable polymer as nanocarrier for treatment of lung cancer. The optimized PCL nanoparticles formulation were developed by screening the use of different tensioactives (sorbitan monostearate, polysorbate 80, polyvinyl alcohol, sodium caproyl hyaluronate and sodium oleyl hyaluronate) in modified nanoprecipitation method. PCL nanoparticles were then characterized for their physicochemical characteristics such as size and size distribution, surface charge and morphology. Optimised PCL nanoparticles developed in this study gave the best results with particles size 87.84 nm and low PDI of 0.116. The surface charge of the nanoparticles were -24.1 mV. PCL nanoparticles were found stabled up to one month stability in different storage conditions. These results suggested that PCL nanoparticles in this study could be successful nanocarrier for lung cancer hydrophilic drug such as docetaxcel for lung cancer treatment.


Poly-ɛ-caprolactone nanoparticles; nanocarrier; pulmonary delivery system; lung cancer

Full Text:



W. Eberhardt and S. Korfee, "New approaches for small-cell lung cancer: local treatments," Cancer Control, vol. 10, no. 4, pp. 289-296, 2003.

Sawyer, A. J., Piepmeier, J. M. and Saltzman, W. M., "New methods for direct delivery of chemotherapy for treating brain tumors," Yale J Biol Med, vol. 79, pp. 141-152, 2006.

Limsoo P. et al, "Drug release mechanism of paclitaxel from a chitosan–lipid implant system: Effect of swelling, degradation and morphology," Eur J Pharm Biopharm, vol. 69, pp. 149-157, 2008.

Zarogoulidis P. et. al, "Inhaled chemotherapy in lung cancer: future concept of nanomedicine," Int J Nanomedicine, vol. 7, pp. 1551-1572, 2012.

Minchinton, A. I. and Tannock, I. F. , "Drug penetration in solid tumours," Nat Rev Cancer, vol. 6, pp. 583-592, 2006.

Gaucher, G., Marchessault, R. H. and Leroux, J.C., "Polyester-based micelles and nanoparticles for the parenteral delivery of taxanes," J Control Release, vol. 143, pp. 2-12, 2010.

C. Vauthier and K. Bouchemal, "Methods for the preparation and manufacture of polymeric nanoparticles," Pharm Res, vol. 26, p. 1025–1058, 2008.

C. E. Mora-Huertas, H. Fessi and A. Elaissari, "Influence of process and formulation parameters on the formation of submicron particles by solvent displacement and emulsification-diffusion methods critical comparison. Adv Colloid Interface Sci 163, 90–," Adv Colloid Interface Sci, vol. 163, pp. 90-122, 2011.

S. M. Moghimi, A. C. Hunter and T. L. Andresen, "Factors controlling nanoparticle pharmacokinetics: an integrated analysis and perspective," Annu. Rev. Pharmacol. Toxicol. 52, 481–503 (2012)., vol. 52, pp. 481-503, 2012.

G. Mittal, D. K. Sahana, V. Bhardwaj and M. N. V. Ravi Kumar, "Estradiol loaded PLGA nanoparticles for oral administration: effect of polymer molecularbehavior in vitro and in vivo," J Control Release, vol. 119, pp. 77-85, 2005.

Jager E. et al, "Sustained release from lipid-core nanocapsules by varying the core viscosity and the particle surface area," J. Biomed. Nanotechnol, vol. 5, pp. 130-140, 2009.

Pignatello, R, Bucolo, C, Ferrara, P, Maltesa, A, Puleo, A and Puglisi, G, "PIGNATELLO REudragit RS100 nanosuspensions for the ophthalmic controlled delivery of ibuprofen," Eur J Pharm, vol. 16, pp. 53-61, 2002.

Das,S, Suresh, P.K and Desmukh, R, "Design of Eudragit RL 100 Nanoparticles by nanoprecipitation method for ocular drug delivery. Nanomedicine," Nanotechnology, Biology, and Medicine, vol. 6, pp. 318-323, 2010.


  • There are currently no refbacks.

Copyright (c) 2017 eProceedings Chemistry

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Copyright © 2016 Department of Chemistry, Universiti Teknologi Malaysia.

Disclaimer : This website has been updated to the best of our knowledge to be accurate. However, Universiti Teknologi Malaysia shall not be liable for any loss or damage caused by the usage of any information obtained from this web site.
Best viewed: Mozilla Firefox 4.0 & Google Chrome at 1024 × 768 resolution.